|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Long Z, Liu W, Lin L, et al: Disease
burden analysis of esophageal cancer in China from 1990 to 2017.
Chin J Chronic Disease Prevention Control. 29:571–575, 581.
2021.
|
|
4
|
Li MX, Cheng WG, Chen P, et al:
Identification and prognostic analysis of key genes in lymph node
metastasis of esophageal squamous cell carcinoma. J Natural Sci Hun
Normal Univ. 44:92–100. 201.
|
|
5
|
Short MW, Burgers KG and Fry VT:
Esophageal cancer. Am Fam Physician. 95:22–28. 2017.PubMed/NCBI
|
|
6
|
Kyle JN, Mary S and Subhasis M: Esophageal
cancer: A review of epidemiology, pathogenesis, staging workup and
treatment modalities. World J Gastrointest Oncol. 6:112–120.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Degterev A, Huang Z, Boyce M, Li Y, Jagtap
P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA and Yuan J:
Chemical inhibitor of nonapoptotic cell death with therapeutic
potential for ischemic brain injury. Nat Chem Biol. 1:112–119.
2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Marshall KD and Baines CP: Necroptosis: Is
there a role for mitochondria? Front Physiol. 5:323–328.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Declercq W, Vanden BT and Vandenabeele P:
RIP kinases at the crossroads of cell death and survival. Cell.
138:229–232. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Krysko O, Aaes TL, Kagan VE, D'Herde K,
Bachert C, Leybaert L, Vandenabeele P and Krysko DV: Necroptotic
cell death in anti-cancer therapy. Immunol Rev. 280:207–219.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jiao D, Cai Z, Choksi S, Ma D, Choe M,
Kwon HJ, Baik JY, Rowan BG, Liu C and Liu ZG: Necroptosis of tumor
cells leads to tumor necrosis and promotes tumor metastasis. Cell
Res. 28:868–870. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan
K, Cheng H, Jin K, Ni Q, Yu X and Liu C: The role of necroptosis in
cancer biology and therapy. Mol Cancer. 18(100)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Snyder AG, Hubbard NW, Messmer MN, Kofman
SB, Hagan CE, Orozco SL, Chiang K, Daniels BP, Baker D and Oberst
A: Intratumoral acti-vation of the necroptotic pathway components
RIPK1 and RIPK3potentiates anti tumor immunity. Sci Immunol.
4(eaaw2004)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yang Z, Jiang B, Wang Y, Ni H, Zhang J,
Xia J, Shi M, Hung LM, Ruan J, Mak TW, et al: 2-HG inhibits
necroptosis by Stim-ulating dnmt1-dependent hypermethylation of the
RIP3 promoter. Cell Rep. 19:1846–1857. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP,
Huo L, Scott A, Wang Y, Ma L, et al: LncRNA PVT1 up-regulation is a
poor prognosticator and serves as a therapeutic target in
esophageal adenocarcinoma. Mol Cancer. 18(141)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Nugues A, ElBouazzati H, Hétuin D, Berthon
C, Loyens A, Bertrand E, Jouy N, Idziorek T and Quesnel B: RIP3 is
downregulated in human myeloid leukemia cells and modulates
apoptosis and caspase-mediated p65/RelA cleavage. Cell Death Dis.
5(e1384)2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Höckendorf U, Yabal M, Herold T,
Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger
F, Heuser M, et al: RIPK3 restricts myeloid leukemogenesis by
promoting cell death and differentiation of leukemia initiating
Cells. Cancer Cell. 30:75–91. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Koo G, Morgan MJ, Lee D, Kim WJ, Yoon JH,
Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, et al:
Methylation-dependent loss of RIP3 expression in cancer represses
programmed necrosis in response to chemotherapeutics. Cell Re.
25:707–725. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bozec D, luga AC, Roda G, Dahan S and
Yeretssian G: Critical function of thenecroptosis adaptor RIPK3 in
protecting from intestinal tumorigenesis. Oncotarget.
7:46384–46400. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu X, Zhou M, Mei L, Ruan J, Hu Q, Peng
J, Su H, Liao H, Liu S, Liu W, et al: Key roles of necroptotic
factors in promoting tumor growth. Oncotarget. 7:22219–22233.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Schmidt SV, Seibert S, Walch-Ruckheim B,
Vicinus B, Kamionka EM, Pahne-Zeppenfeld J, Solomayer EF, Kim YJ,
Bohle RM, Smola S, et al: RIPK3 expression in cervical cancer cells
is required for PolyIC-induced necroptosis, IL-1α release, and
efficient paracrine dendritic cell activation. Oncotarget.
6:8635–8647. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Takemura R, Takaki H, Okada S, Shime H,
Akazawa T, Oshiumi H, Matsumoto M, Teshima T and Seya T: Poly1:
C-induced, TLR3 RIP3-dependent necroptosis backs up immune
effector-mediated tumor elimination in vivo. Cancer Immunol Res.
3:902–914. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yatim N, Jusforgues-Saklani H, Orozco S,
Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A
and Albert ML: RIPKI and NF-κB signaling in dying cells determines
cross-priming of CD8+Tcells. Science. 350:328–334.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kang YJ, Bang BR, Han KH, Hong L, Shim EJ,
Ma J, Lerner RA and Otsuka M: Regulation of NKT cell mediated
immune responses to tumours and liver inflammation by mitochondrial
PGAM5-Drpl signalling. Nat Commun. 6(8371)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Strilic B, Yang L, Albarrán-Juárez J,
Wachsmuth L, Han K, Müller UC, Pasparakis M and Offermanns S:
Tumour-cell-induced endothelial cell necroptosis via death receptor
6 promotes metastasis. Nature. 536:215–218. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Seifert L, Werba G, Tiwari S, Giao Ly NN,
Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH,
et al: The necrosome promotes pancreatic oncogenesis via CXCL1 and
Mincle-induced immune suppression. Nature. 532:245–249.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dragomir MP, Kopetz S, Ajani JA and Calin
GA: Non-coding RNAs in GI cancers: From cancer hallmarks to
clinical utility. Gut. 69:748–763. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhao Z, Liu H, Zhou X, Fang D, Ou X, Ye J,
Peng J and Xu J: Necroptosis-Related lncRNAs: Predicting prognosis
and the distinction between the cold and hot tumors in gastric
cancer. J Oncol. 2021(6718443)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xue ST, Zheng B, Cao SQ, Ding JC, Hu GS,
Liu W and Chen C: Long non-coding RNA LINC00680 functions as a
ceRNA to promote esophageal squamous cell carcinoma progression
through the miR-423-5p/PAK6 axis. Mol Cancer. 21(69)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xu JH, Chen RZ, Liu LY, Li XM, Wu CP, Zhou
YT, Yan JD and Zhang ZY: LncRNA ZEB2-AS1 promotes the
proliferation, migration and invasion of esophageal squamous cell
carcinoma cell through miR-574-3p/HMGA2 axis. Eur Rev Med Pharmacol
Sci. 25(3397)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang K, Liu F, Liu CY, An T, Zhang J, Zhou
LY, Wang M, Dong YH, Li N, Gao JN, et al: The long noncoding RNA
NRF regulates programmed necrosis and myocardial injury during
ischemia and reperfusion by targeting miR-873. Cell Death Differ.
23:1394–1405. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Huang J, Xu Z, Teh BM, Zhou C, Yuan Z, Shi
Y and Shen Y: Construction of a necroptosis-related lncRNA
signature to predict the prognosis and immune microenvironment of
head and neck squamous cell carcinoma. J Clin Lab Anal.
36(e24480)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Luo L, Li L, Liu L, Feng Z, Zeng Q, Shu X,
Cao Y and Li Z: A Necroptosis-Related lncRNA-Based signature to
predict prognosis and probe molecular characteristics of stomach
adenocarcinoma. Front Genet. 13(833928)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu L, Huang L, Chen W, Zhang G, Li Y, Wu
Y, Xiong J and Jie Z: Comprehensive Analysis of Necroptosis-Related
Long Noncoding RNA immune infiltration and prediction of prognosis
in patients with colon cancer. Front Mol Biosci.
9(811269)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen F, Yang J, Fang M, Wu Y, Su D and
Sheng Y: Necroptosis-related lncRNA to establish novel prognostic
signature and predict the immunotherapy response in breast cancer.
J Clin Lab Anal. 36(e24302)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yatim N, Jusforgues-Saklani H, Orozco S,
Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A
and Albert ML: RIPK1 and NF-κB signaling in dying cells determines
cross-priming of CD8 + T cells. Science. 350:328–334.
2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhao Z, Liu H, Zhou X, Fang D, Ou X, Ye J,
Peng J and Xu J: Necroptosis-related lncRNAs: Predicting prognosis
and the distinction between the cold and hot tumors in gastric
cancer. J Oncol. 2021(6718443)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang
X, Zeng W, Ma L and Xie J: Immune-related lncRNA to construct novel
signature and predict the immune landscape of human hepatocellular
carcinoma. Mol Ther Nucleic Acids. 22:937–947. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Geeleher P, Cox NJ and Huang RS: Clinical
drug response can be predicted using baseline gene expression
levels and in vitro drug sensitivity in cell lines. Genome Biology.
15(R47)2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yang C and Chen K: Long Non-Coding RNA in
esophageal cancer: A review of research progress. Pathol Oncol Res.
28(1610140)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jin-Ming T and Wen-Xiang W: The role of
LNCRNA ZFAS1 in esophageal Carcinoma and its mechanism. Chin J
Biol. 762–768. 2020.
|
|
42
|
Tang D, Wang B, Khodahemmati S, Li J, Zhou
Z, Gao J, Sheng W and Zeng Y: A transcriptomic analysis of
malignant transformation of human embryonic esophageal epithelial
cells by HPV18 E6E7. Transl Cancer Res. 9:1818–1832.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li Z, Zhou Y, Tu B, Bu Y, Liu A and Kong
J: Long noncoding RNA MALAT1 affects the efficacy of radiotherapy
for esophageal squamous cell carcinoma by regulating Cks1
expression. J Oral Pathol Med. 46:583–590. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Farooqi A, Legaki E, Gazouli M, Rinaldi S
and Berardi R: MALAT1 as a versatile regulator of cancer: Overview
of the updates from predatory role as competitive endogenous RNA to
mechanistic insights. Curr Cancer Drug Targets: Jul 30, 2020. doi:
10.2174/1568009620999200730183110 (Epub ahead of print).
|
|
45
|
Seifert L, Werba G, Tiwari S, Giao Ly NN,
Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH,
et al: The necrosome promotes pancreatic oncogenesis via CXCL1 and
Mincle-Induced immune suppression. Nature. 532:245–249.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Snyder AG, Hubbard NW, Messmer MN, Kofman
SB, Hagan CE, Orozco SL, Chiang K, Daniels BP, Baker D and Oberst
A: Intratumoral activation of the necroptotic pathway components
RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol.
4(eaaw2004)2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
McComb S, Cheung HH, Korneluk RG, Wang S,
Krishnan L and Sad S: cIAP1 and cIAP2 limit macrophage necroptosis
by inhibiting Rip1and Rip3 activation. Cell Death Differ.
19:1791–1801. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Liu Y, Chen Y, Tan L, Zhao H and Xiao N:
Linc00299/miR-490-3p/AURKA axis regulates cell growth and migration
in atherosclerosis. Heart Vessels. 34:1370–1380. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chang M, Liu G, Wang Y, Lv H and Jin Y:
Long non-coding RNA LINC00299 knockdown inhibits ox-LDL-induced T/G
HA-VSMC injury by regulating miR-135a-5p/XBP1 axis in
atherosclerosis. Panminerva Med. 64:38–47. 2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Manoochehri M, Jones M, Tomczyk K,
Fletcher O, Schoemaker MJ, Swerdlow AJ, Borhani N and Hamann U: DNA
methylation of the long intergenic noncoding RNA 299 gene in
triple-negative breast cancer: Results from a prospective study.
Sci Rep. 10(11762)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Talkowski ME, Maussion G, Crapper L,
Rosenfeld JA, Blumenthal I, Hanscom C, Chiang C, Lindgren A,
Pereira S, Ruderfer D, et al: Disruption of a large intergenic
noncoding RNA in subjects with neurodevelopmental disabilities. Am
J Hum Genet. 91:1128–1134. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Li M, Wang J, Liu D and Huang H: High
throughput sequencing reveals differentially expressed lncRNAs and
circRNAs, and their associated functional network, in human
hypertrophic scars. Mol Med Rep. 18:5669–5682. 2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Kakeji Y, Oshikiri T, Takiguchi G, Kanaji
S, Matsuda T, Nakamura T and Suzuki S: Multimodality approaches to
control esophageal cancer: Development of chemoradiotherapy,
chemotherapy, and immunotherapy. Esophagus. 18:25–32.
2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Frankel T, Lanfranca MP and Zou W: The
role of tumor microenvironment in cancer immunotherapy. Adv Exp Med
Biol. 1036:51–64. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pitt JM, Marabelle A, Eggermont A, Soria
JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment:
Removing obstruction to anticancer immune responses and
immunotherapy. Ann Oncol. 27:1482–1492. 2016.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Nishikawa H and Koyama S: Mechanisms of
regulatory T cell infiltration in tumors: Implications for
innovative immune precision therapies. J Immunother Cancer.
9(e002591)2021.PubMed/NCBI View Article : Google Scholar
|
